Skip to Content


In this month's "Hot Topic," Dragan Jevremovic, M.D., Ph.D., reviews the current state of testing for diagnosis, therapy, and stratification of patients with multiple myeloma.

By MCL Education • October 12, 2020

The results are part of a comprehensive study of 16,175 cases performed at Mayo Clinic over an 11-year period.

By Suzanne Ferguson • September 10, 2020

Horatiu Olteanu, M.D., Ph.D., gives an overview of the new T-cell receptor (TCR) β-chain constant region (TRBC1) flow cytometry marker, which is now included in Mayo Clinic Laboratories' routine diagnostic T-cell flow cytometry panel. He discusses when this testing should be ordered, how the addition of TCRBC1 compares to previous testing approaches, and how this marker can assist ordering physicians.

By Alyssa Frank • August 11, 2020

Rajiv Pruthi, M.B.B.S., gives an overview of this testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • June 3, 2020

Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.

By Christoph Bahn • March 10, 2020

Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.

By Samantha Rossi • February 25, 2020

October 2-3, 2020 | Rochester, MN
This Mayo Clinic conference will provide an update on interpretation and optimal application of standard and evolving test repertoire to diagnosis non-malignant blood disorders.

By MCL Education • February 20, 2020

Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Samantha Rossi • February 7, 2020

As a pioneer in the field, the Mayo Clinic plays an integral role by discovering new tests and treatments for plasma cell disorders. Our algorithmic approach ensures that the right tests are ordered at the right time, and that health care providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their field.

By Alyssa Frank • January 18, 2020

With input from Mayo Clinic oncologists, our laboratories have developed a menu of next-generation sequencing (NGS) oncology panels. These panels aid in the diagnosis and management of patients with cancer and are optimized for clinically relevant genes and actionable targets consistent with current oncology guidelines.

By Alyssa Frank • September 1, 2019

In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53 sequencing in these patients.

By MCL Education • August 12, 2019

David Viswanatha, M.D., a hematopathologist and co-director of the molecular hematology and complete genome sequencing laboratories at Mayo Clinic, provides an overview of BCR/ABL1 testing, discusses the best testing methods, NCCN/ELN criteria guidelines, why FISH testing is no longer routinely available at Mayo Clinic, and what test to order at what time for CML patients.

By Alyssa Frank • July 16, 2019

September 19, 2019 | Scottsdale, AZ
This preconference session will familiarize participants with the application and utility of molecular oncology testing. Participants learn the fundamental features of molecular testing platforms as faculty review clinical scenarios in which molecular testing is appropriate.

By MCL Education • July 15, 2019